Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005

Anesthesia and Analgesia

Volumn 109, Issue 4, 2009, Pages 1162-1166

  Brady, Joanne E ^a   Sun, Lena S ^a   Rosenberg, Henry ^b,c   Li, Guohua ^a,d  

^a Columbia University ^*  (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Malignant Hyperthermia Association of the United States   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANESTHESIA; ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; UNITED STATES; ADOLESCENT; CHILD; DATA BASE; EPIDEMIOLOGY; HOSPITAL; HOSPITALIZATION; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RISK FACTOR; SEX DIFFERENCE; STATISTICS; TIME;

ADOLESCENT; ADULT; ANESTHESIA; CHILD; CHILD, PRESCHOOL; DATABASES AS TOPIC; FEMALE; HEALTH CARE SURVEYS; HOSPITALIZATION; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; NEW YORK; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 70349573495     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181ac1548     Document Type: Article

References (25)

1. Torpy J, Lynm C, Glass RM. Malignant hyperthermia. JAMA 2005;293:2958
2. Litman R, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005;293:2918-2924 (Pubitemid 41029146)
3. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21
4. Kozack J, MacIntyre D. Malignant hyperthermia. Phys Ther 2001;81:945-951
5. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-779 (Pubitemid 24128939)
6. Larach MG, Landis JR, Bunn JS, Diaz M. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. Anesthesiology 1992;76:16-27
7. Larach M. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989;69:511-515 (Pubitemid 20037376)
8. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European malignant hyperthermia group. Acta Anaesthesiol Scand 1997;41:955-966
9. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth 1984;56:1267-1269
10. Britt B, Kalow W. Malignant hyperthermia: a statistical review. Can J Anaesth 1970;17:293-315
11. Sessler DI. Malignant hyperthermia. Acta Anaesthesiol Scand 1996;109:25-30
12. Bachand M, Vachon N, Boisvert M, Mayer F, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi- Temiscamingue. Can J Anaesth 1997;44:696-701 (Pubitemid 27458671)
13. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg 1985;34:395-396
14. Monnier N, Krivosic-Horber R, Payen J, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002;97:1067-1074 (Pubitemid 35265557)
15. Ibarra CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi Y, Ochiai R, Nishino I. Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006;104:1146-1154
16. Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009;110:89-94
17. Moore J, Rice E. Malignant hyperthermia. Am Fam Physician 1992;45:2245-2251
18. Denborough MA. Malignant hyperthermia. Lancet 1998;352: 1131-1136
19. Tomarken J, Britt B. Malignant hyperthermia. Ann Emerg Med 1987;16:1253-1265
20. Donnelly A. Malignant hyperthermia: epidemiology, pathophysiology, treatment. AORN J 1994;59:393-405
21. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. A multicenter study. Anesthesiology 1982;56:254-262
22. Charlson ME, Pompei P, Ales KL, Mac Kenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
24. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139 (Pubitemid 41587600)
25. Migita T, Mukaida K, Kawamoto M, Kobayashi M, Yuge O. Fulminant-type malignant hyperthermia in Japan: cumulative analysis of 383 cases. J Anesth 2007;21:285-288 (Pubitemid 46692025)